Literature DB >> 9605439

Gene amplification and increased expression of the reduced folate carrier in transport elevated K562 cells.

S C Wong1, L Zhang, S A Proefke, B Hukku, L H Matherly.   

Abstract

The molecular bases for the 6-fold elevated methotrexate transport capacity of K562.4CF cells (Matherly et al., Cancer Res. 51: 3420-3426, 1991) were studied with reduced folate carrier (RFC) cDNA, genomic, and antibody probes. Southern analysis showed that RFC gene copies were increased (approximately 4- to 5-fold) in K562.4CF over wild-type K562 cells. Fluorescence in situ hybridization using a genomic RFC probe confirmed the localization of the RFC gene to the q-arm of chromosome 21. In K562.4CF cells, the frequent loss of a normal copy of chromosome 21 (61% of metaphases) was accompanied by RFC gene amplification and translocations of amplified RFC gene fragments to several (2 to 6) different chromosomal loci not seen in wild-type cells. Particularly intense RFC signals were mapped to homogeneously staining regions in chromosomes 2 and 15. Increased RFC gene copies were accompanied by a similar increase in the major 3.1 kb RFC transcript by northern blotting and an approximately 7-fold elevated level of the broadly migrating (80-95 kDa) RFC protein on a western blot probed with an RFC C-terminal peptide antibody. These results demonstrate that selection of cells with a growth-limiting concentration of reduced folates (0.4 nM of leucovorin) is sufficient to promote chromosomal aberrations, including gene amplification and translocations that result in increased RFC expression and folate transport.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605439     DOI: 10.1016/s0006-2952(97)00639-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia.

Authors:  J L Wiemels; R N Smith; G M Taylor; O B Eden; F E Alexander; M F Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter.

Authors:  Johnathan R Whetstine; Robin M Flatley; Larry H Matherly
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

3.  SLC19A1 pharmacogenomics summary.

Authors:  Sook Wah Yee; Li Gong; Ilaria Badagnani; Kathleen M Giacomini; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

4.  Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.

Authors:  Shu-mei Wang; Lu-lu Sun; Wei-xin Zeng; Wan-shui Wu; Guo-liang Zhang
Journal:  Med Oncol       Date:  2014-06-14       Impact factor: 3.064

5.  Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.

Authors:  S Jabeen; L Holmboe; G I G Alnæs; A M Andersen; K S Hall; V N Kristensen
Journal:  Pharmacogenomics J       Date:  2015-03-17       Impact factor: 3.550

6.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

7.  Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.

Authors:  J Wolf; T Stranzl; M Filipits; G Pohl; R Pirker; B Leeb; J S Smolen
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.